Erica Cassimere to Neoplasms
This is a "connection" page, showing publications Erica Cassimere has written about Neoplasms.
Connection Strength
0.236
-
Folk WP, Kumari A, Iwasaki T, Cassimere EK, Pyndiah S, Martin E, Homlar K, Sakamuro D. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. Int J Mol Sci. 2021 Dec 11; 22(24).
Score: 0.084
-
Folk WP, Kumari A, Iwasaki T, Pyndiah S, Johnson JC, Cassimere EK, Abdulovic-Cui AL, Sakamuro D. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. J Biol Chem. 2019 04 05; 294(14):5700-5719.
Score: 0.069
-
Lundgaard GL, Daniels NE, Pyndiah S, Cassimere EK, Ahmed KM, Rodrigue A, Kihara D, Post CB, Sakamuro D. Identification of a novel effector domain of BIN1 for cancer suppression. J Cell Biochem. 2011 Oct; 112(10):2992-3001.
Score: 0.042
-
Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal. 2011 Mar 29; 4(166):ra19.
Score: 0.040